The commencement of Jupiter Life Line Hospitals Limited's Initial Public Offering (IPO) unfolded on Wednesday, specifically on September 6th, ushering in a subscription window that will remain open until September 8th, providing investors with an opportunity to partake in this public offering.
This IPO encompasses a two-pronged approach, consisting of a fresh issuance of equity shares amounting to a substantial Rs 542 crore and an offer-for-sale (OFS) mechanism, permitting the sale of up to 4.45 million equity shares. Collectively, this translates to an impressive total issue size of approximately Rs 869 crore.
Crucially, prior to this IPO, the company garnered a commendable infusion of Rs 260.72 crore from a cohort of anchor investors, featuring notable names such as the Abu Dhabi Investment Authority, Goldman Sachs, Nomura Funds, Government of Singapore, HSBC Global, and Fidelity Funds, among other distinguished entities.
A noteworthy facet of this IPO journey is the robust performance of Jupiter Life Line Hospitals in the grey market, as it has consistently maintained a healthy grey market premium (GMP) in the range of Rs 200-218 in recent days. This heightened interest can be attributed to the successful market listings of enterprises like Vishnu Prakash R Punglia and Aeroflex Industries, which have buoyed market sentiment.
Jupiter Life Line Hospitals Limited stands as a prominent healthcare provider, extending a wide spectrum of specialized medical services within the Mumbai Metropolitan Area (MMR) and the broader western region of India. As of March 31, 2023, the company takes pride in its impressive total bed capacity, boasting a substantial 1,194 beds spread across three well-established hospitals.
Founded in 2007, the company manages these healthcare facilities under the esteemed "Jupiter" brand, strategically positioned in Thane, Pune, and Indore. To further fortify its presence and service offerings, Jupiter Hospitals is actively engaged in the construction of a cutting-edge multispecialty hospital located in Dombivli, Maharashtra. This sprawling facility, encompassing an expansive 600,000 square feet, is set to accommodate over 500 beds, significantly enhancing the company's ability to cater to the healthcare needs of the region. The construction of this pivotal hospital project commenced in April 2023, marking a significant step in the company's expansion strategy.
Several prominent brokerages have offered a favorable 'subscribe' rating to the IPO, grounded in their analysis of the company's long-term growth prospects, valuation, and relative standing among industry peers. Leading the pack, Reliance Securities, SBI Securities, and Ventura are among the brokerage firms that have expressed confidence in the IPO, endorsing it with a 'subscribe' recommendation.
Reliance Securities, for instance, highlighted the company's strategic location within the robust MMR region, characterized by a consistently growing population. Notably, MMR boasts a robust bed-to-population ratio of 33.0 beds per 10,000 people, surpassing the state average for Maharashtra, which stands at 20 beds per 10,000 people. With an estimated population of 20.96 million, Jupiter Life Line Hospitals aims to bolster occupancy rates, optimize equipment utilization, and uphold its commitment to clinical excellence by attracting and retaining high-caliber medical professionals in specific fields.
"The issue is priced at a P/BV (Price-to-Book Value) of 11.41 based on its NAV (Net Asset Value) of Rs. 64.39 as of March 31, 2023. Post IPO, it will emerge as a debt-free entity. Its growth in the healthcare sector, strong financials, cost efficiency, good patient volumes, and expansion into new areas are poised to drive the company's performance in the long term. Hence, we recommend subscribing to the issue from a long-term perspective," stated Reliance Securities in its pre-IPO analysis.
In parallel, SBI Securities assessed the IPO valuation, noting that the company's valuation stands at a FY23 PE (Price-to-Earnings) multiple of 66.1x, an EV/Bed (Enterprise Value per Bed) of Rs 4.8 crore, and an EV/EBITDA (Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization) of 22.9x, all calculated at the upper price band following the post-issue capitalization.
"The IPO appears to be fairly valued across various valuation parameters when compared to its peers. With decent return ratios and margins, the risk-reward profile for long-term investors appears favorable. Investors can consider subscribing to the IPO from a long-term investment perspective," advised the brokerage, underlining the potential merits of participation in this offering.
